Will ophthalmic copra raise blood sugar levels in individuals with diabetes?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 25, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Ophthalmic Corticosteroids and Blood Glucose

No, ophthalmic corticosteroid drops do not clinically raise blood sugar in most diabetic patients, though a small, transient increase may occur in those with well-controlled diabetes that returns to baseline after discontinuation without adverse effects.

Evidence on Systemic Absorption

The concern about ophthalmic corticosteroids raising blood glucose has been directly studied:

  • In diabetic patients receiving intensive topical dexamethasone (8 drops daily for 7 days), no statistically significant alterations in blood glucose levels occurred overall 1
  • No hypoglycemic or hyperglycemic crises were observed in either treatment or control groups 1

Subgroup Considerations

For patients with well-controlled diabetes (glucose ≤135 mg/dL):

  • A statistically significant but clinically minor increase in blood glucose was detected at the start of treatment 1
  • Glucose levels returned to pretreatment baseline after discontinuation of drops without any side effects 1

For patients with uncontrolled diabetes (glucose >135 mg/dL):

  • No statistically significant changes in blood glucose levels were found 1

Clinical Implications

The minimal systemic absorption from topical ophthalmic corticosteroids makes clinically significant hyperglycemia extremely unlikely:

  • The primary concern with ophthalmic corticosteroids in diabetic patients is progression of diabetic retinopathy, not blood glucose elevation 2
  • Blood glucose control remains the key modifiable risk factor for diabetic retinopathy development and progression 2
  • Maintaining HbA1c ≤7% is the target for most diabetic patients to reduce microvascular complications including retinopathy 2

Important Caveats

Monitor patients more carefully if:

  • They have well-controlled diabetes at baseline, as they may experience transient glucose elevation 1
  • They are using intensive dosing regimens (multiple drops daily) 1

The real risk is not hyperglycemia but rather:

  • Increased intraocular pressure from corticosteroid use (steroid response)
  • Potential worsening of diabetic retinopathy if systemic glucose control deteriorates 2

References

Research

The effect of intense, short-term topical dexamethasone disodium phosphate eyedrops on blood glucose level in diabetic patients.

Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde, 2007

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.